Belgian biotechnology company UCB says its proprietary arthritis drug Cimzia, together with methotrexate reduces symptoms of disease and inhibited progression of joint damage in adult patients with active rheumatoid arthritis (RA), with sustained results for up to one year.

 

A prepared company release said the one year study showed Cimzia, together with MTX, had a rapid and significant effect in reducing the signs and symptoms of active RA as early as week one. Patients treated with Cimzia, together with MTX, experienced significant improvements in physical function and quality of life from Week 1 and sustained for up to one year.

 "Cimzia is the first anti-TNF to demonstrate such early results in disease progression. UCB looks forward to bringing these benefits to people who suffer from RA once the regulatory review process is completed," said Iris Loew-Friedrich, Chief Medical Officer, UCB.  "With more than five million people suffering from RA across the globe, RAPID 1 showed that, upon successful regulatory review, Cimzia can provide a treatment option for patients seeking a rapid and effective therapy to manage this debilitating condition," said principle investigator Professor Bernard Combe, Montpellier University Hospital, France.